Allogeneic Hematopoietic Cell Transplant for Prolymphocytic Leukemia  by Kalaycio, Matt E. et al.
From the
Intern
Colle
son C
Hosp
Hous
Portla
8Celg
garet
Bone
Florid
12Nat
sity of
Financial d
Correspon
sig C
nue, C
Received A
 2010 Am
1083-8791
doi:10.101Allogeneic Hematopoietic Cell Transplant
for Prolymphocytic Leukemia
Matt E. Kalaycio,1 Manisha Kukreja,2 Ann E. Woolfrey,3 Jeffrey Szer,4 Jorge Cortes,5
Richard T. Maziarz,6 Brian J. Bolwell,1 Andreas Buser,7 Edward Copelan,1 Robert Peter Gale,8
Vikas Gupta,9 Dipnarine Maharaj,10 David I. Marks,11 Steven Z. Pavletic,12
Mary M. Horowitz,2 Mukta Arora13The poor prognosis of patients with prolymphocytic leukemia (PLL) has led some clinicians to recommend
allogeneic hematopoietic cell transplant (HCT). However, the data to support this approach is limited to
case-reports and small case series. We reviewed the database of the Center for International Blood and
Marrow Transplant Research (CIBMTR) to determine outcomes after allotransplant for patients with PLL.
We identified 47 patients with a median age of 54 years (range: 30-75 years). With a median follow-up of
13 months, progression-free survival (PFS) was 33% (95% confidence interval [CI] 20%-47%) at 1 year.
The most common cause of death was relapse or progression in 49%. The cumulative incidence of treat-
ment-related mortality (TRM) at 1-year posttransplant was 28%. The small patient population prohibited
prognostic factor analysis, but these data support consideration of allotransplant for PLL. Further study of
a larger population of patients is needed to determine which patients are more likely to benefit.
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Prolymphocytic leukemia (PLL) actually comprises
2 rare lymphoproliferative disorders [1]: (1) T cell PLL
(T-PLL) and (2) B cell PLL (B-PLL).T-PLL expresses
CD2,CD3, andCD7, but notTdTorCD1a [2]. A spe-
cific cytogenetic abnormality, inv(14)(q11q32) or
t(14;14)(q11q32), which results in a rearrangement of
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6/j.bbmt.2009.11.021located within the TCL1 locus, occurs in most cases
ofT-PLL [3-5]. B-PLLhas an immune phenotype sim-
ilar to chronic lymphocytic leukemia (CLL); the cells
express the pan-B antigens CD19, CD20, and CD22,
but not CD5 [6].
PLL has a poor prognosis with standard therapies.
Purine analogs are reasonably active and induce remis-
sion in about 50% of patients. Unfortunately, 90% of
these responses are partial and the median duration of
response is\1 year [2,7-11].
Monoclonal antibodies (mAbs) are active in PLL.
Alemtuzumab induces remission in about 75% of pa-
tients with advanced T-PLL [12], but the median re-
sponse duration is \1 year [13]. Better results are
achieved when alemtuzumab is given as initial therapy;
nearly all patients respond and some remain in remis-
sion for years [14]. There is less experience with ritux-
imab in B-PLL, with anecdotal reports of durable
responses [15].
Because of the poor prognosis with standard treat-
ments, hematopoietic cell transplant (HCT) has been
explored as therapy for advanced PLL. The largest
published series included 11 patients with T-PLL
treated with auto- or allotransplants. Three of the 4 pa-
tients receiving allotransplant were alive up to
24 months following transplant [12]. Case reports
also suggest the potential efficacy of allotransplants
for PLL [16-19]. However, the efficacy of this543
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the databases of the Center for International Blood
and Marrow Transplant Research (CIBMTR) to de-
termine outcomes of allotransplants for PLL.MATERIALS AND METHODS
Data Sources
A formal affiliation of the research division of the
NationalMarrowDonor Program (NMDP), the Inter-
national Bone Marrow Transplant Registry (IBMTR)
and the Autologous Blood and Marrow Transplant
Registry (ABMTR) led to establishment of the
CIBMTR in 2004. The CIBMTR is a voluntary work-
ing group of more than 450 transplant centers world-
wide that contribute detailed data on consecutive
allogeneic HCTs to the Statistical Center at the Medi-
cal College of Wisconsin in Milwaukee or the NMDP
Coordinating Center in Minneapolis. Approximately
two-thirds of all active transplantation centers world-
wide report data to the registry. The registry database
includes information on 40% to 45% of all patients
whohave received an allotransplant since 1970,with an-
nual updates. The CIBMTR collects data at 2 levels:
registration and research. Registration data include dis-
ease type, age, sex, pretransplant performance status,
disease stage and chemotherapy responsiveness, date
of diagnosis, donor and graft type (BM - and/or
blood-derived stem cells), high-dose conditioning reg-
imen, posttransplant engraftment, disease recurrence
and survival, development of a new malignancy, and
cause of death. Requests for data on disease recurrence
or death for registered patients are at 6-month intervals.
All CIBMTR centers contribute registration data on all
patients. Research data are collected on subsets of
registered patients selected using a weighted randomi-
zation scheme, including comprehensive pre- and
posttransplant clinical information. Compliance is as-
sessedbyperiodic audits, andaccuracyof data is ensured
by computerized record checks, physician review of
submitted data, and on-site audits. Observational
studies conducted by the CIBMTR are done with
a waiver of informed consent and in compliance with
HIPAA regulations as determined by the institutional
review board and Privacy Officer of Medical College
of Wisconsin.Patients
For the purposes of this analysis, the CIBMTR da-
tabases were queried for all patients with PLL treated
by allogeneic HCT from 1995 through 2005. The di-
agnosis of PLL was made at the treatment center, and
there was no central review of histologic or immuno-
phenotypic data.Statistical Analysis
Patient-, disease- and transplant-related factors
were described. The product-limit estimator proposed
by Kaplan-Meier was used to estimate the median and
range of the follow-up time. Progression free survival
(PFS) is defined as survival without relapse, progres-
sion, or persistent disease. Treatment failure events
are disease relapse, progression, or persistent disease
or death, and are summarized by a survival curve.
Time to event is measured from the date of transplant.
Probabilities of overall survival (OS) and PFS were cal-
culated using the Kaplan-Meier estimator, with the
variance estimated by Greenwood’s formula. Patients
were censored at date of last known follow-up. Cumu-
lative incidence estimates were calculated for other
endpoints to account for competing risks.RESULTS AND DISCUSSION
Forty-seven patients with PLL received allotrans-
plants at 29 centers (Table 1). Most donors (77%)
were matched unrelated persons. Twenty-three pa-
tient-unrelated donor pairs (64%) HLA matched at 8
of 8 loci by high- or low-resolution typing at HLA-A,
-B, and DRB1 were considered ‘‘well matched’’ [20].
Twelve patient-unrelated donor pairs were partially
matched or mismatched and 1 pair was unknown.
The median follow-up for all patients from the time
of allotransplant was 13 months (range: 6-81).
Grade II-IV acute graft-versus-host disease
(aGVHD) developed in 52% (95% confidence interval
[CI] 38%-66%) of transplant recipients. The 1-year
incidence of chronic GVHD (cGVHD) was 42% (CI
28%-57%). The cumulative incidence of treatment-
related mortality at 1-year posttransplant was 28%
(CI 16-42). One year incidence of relapse or progres-
sion was 39% (CI 25-53). Of the 33 deaths, 16 (49%)
were because of progression of leukemia, 5 (15%)
were from GVHD, and 4(12%) were from infection.
With a median follow-up of survivors of 13 months
(range: 6-81 months), the 1 year PFS is 33% (CI 20-
47) (Figure 1). The 1-year OS is 48% (CI 33-62), with
amedianOSof 11.2months (CI8-14).Therewasno sig-
nificant difference in 1-yearOS between patients treated
with nonmyeloablative (NMA) versus myeloablative
(MA) transplant, sibling versusmatched unrelated donor
transplant, age .54 years versus age 54 years or less, B
cell versus T cell PLL, or in first complete remission
(CR1) versus not in first CR1.Neither was there a differ-
ence in 2-year OS between patients with either aGVHD
or cGVHD compared to those without GVHD.
MedianPFS for the 21 patientswithT-PLLwas 5.1
months and 3.5months for the 11 patients with B-PLL.
The16patients inCRat transplant had amedianPFSof
8.9 months and the 34 patients transplanted with
HLA-matched siblingorHLA-well-matchedunrelated
Table 1. Characteristics of All the Patients Who Underwent
Allotransplant for Prolymphocytic Leukemia and Reported to
the CIBMTR, from 1995 to 2006
Variable N Eval N (%)
Patient-related
Number of patients 47
Number of centers 29
Age, median (range), years 47 54 (30-75)
Age at transplant, years 47
31-40 4 (9)
41-50 11 (23)
>50 32 (68)
Male sex 47 31 (66)
Race White 47 41 (87)
Karnofsky score at transplant 40
#80% 10 (25)
>80% 30 (75)
Disease-related
Interval from diagnosis to transplant (months) 47 11 (2-78)
Immunophenotype 47
B cell PLL 11 (23)
T cell PLL 21 (45)
PLL (type unknown, confirmed with
centers)
15 (32)
Splenectomy 46
Yes 6 (13)
No 40 (87)
Disease stage at HCT 45
Complete remission 16 (36)
Partial remission 8 (18)
Refractory 21 (46)
Transplant-related
Donor/recipient gender match 47
M-M 22 (47)
M-F 12 (26)
F-M 9 (19)
F-F 4 (9)
Donor 47
HLA-identical sibling 11 (23)
Unrelated 36 (77)
Donor-recipient HLA match* 47
Matched sibling 11 (24)
Well matched 23 (49)
Mismatched 12 (25)
Unknown 1 (2)
Donor-recipient CMV status 45
+/+ 11 (24)
+/2 3 (7)
2/+ 15 (33)
2/2 16 (36)
Conditioning regimen 47
>9 mg/kg busulfan or >500 cGy radiation
(myeloablative)
19 (40)
<9 mg/kg busulfan or <500 cGy radiation
(reduced intensity)
14 (30)
Neither (melphalan- nor fludarabine-based
regimens)
14 (30)
Graft type 47
Bone marrow 15 (32)
Peripheral blood progenitor cells 31 (66)
Umbilical cord blood 1 (2)
Year of transplant 47
1995-1996 3 (6)
1997-1998 2 (4)
1999-2000 9 (19)
2001-2002 5 (11)
2003-2004 12 (26)
2005-2006 16 (34)
GVHD prophylaxis 47
MTX + CsA ± others 18 (38)
FK506 + MTX ± others 9 (19)
CsA ± others 8 (17)
FK506 ± others 10 (21)
(Continued )
Table 1. (Continued )
Variable N Eval N (%)
T cell depletion 2 (4)
Median follow-up of survivors, months 14 13 (6-81)
PLL indicates prolymphocytic leukemia; GVHD, graft-versus-host
disease; MTX, methotrexate; CsA, cyclosporine; FK506, tacrolimus.
*Well matched was defined as no known disparity at HLA -A, -B, -C, and
-DRB1, partially matched as 1 locus known or likely disparity with their
donors and mismatched as $2 locus disparity.
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were still alive and in remission at the time of data
analysis.
Although most patients with advanced PLL have
poor survival, our data demonstrates that approximately
one-third of patients are alive and progression-free at
1 year. Consistent with some case reports indicating
long-term PFS in a minority of select patients [19,20]
and because there is no other effective therapy that
provides durable remissions, patients with PLL that
are eligible for SCT should consider this option.
Our study is too small and with too heterogenous
of a population to explore potentially important ques-
tions with regard to which patients may ultimately
benefit from an allotransplant. For example, we could
not perform a multivariable analysis to determine
which risk factors, if any, correlated with outcomes.
Nonetheless, our data indicates that at least some pa-
tients may derive sustained benefit from an allotrans-
plant. More and larger studies would be required to
help identify which patients those would be.ACKNOWLEDGMENTS
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